Medical Care
Global Cardiometabolic Diseases Market Research Report 2024
- Apr 15, 24
- ID: 168871
- Pages: 81
- Figures: 161
- Views: 17
Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.
The global Cardiometabolic Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cardiometabolic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cardiometabolic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cardiometabolic Diseases in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cardiometabolic Diseases include Eli Lilly and Company, Bayer AG, Arrowhead Pharmaceuticals, Inc, Novartis AG, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc. and Cardax, Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cardiometabolic Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiometabolic Diseases.
Report Scope
The Cardiometabolic Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cardiometabolic Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiometabolic Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly and Company
Bayer AG
Arrowhead Pharmaceuticals, Inc
Novartis AG
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
AstraZeneca
Alnylam Pharmaceuticals, Inc.
Cardax, Inc
Kowa Company, Ltd.
Segment by Type
ACE Inhibitors
Diuretics
Glucophage
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cardiometabolic Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Cardiometabolic Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cardiometabolic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cardiometabolic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cardiometabolic Diseases in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cardiometabolic Diseases include Eli Lilly and Company, Bayer AG, Arrowhead Pharmaceuticals, Inc, Novartis AG, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc. and Cardax, Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cardiometabolic Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiometabolic Diseases.
Report Scope
The Cardiometabolic Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cardiometabolic Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiometabolic Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly and Company
Bayer AG
Arrowhead Pharmaceuticals, Inc
Novartis AG
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
AstraZeneca
Alnylam Pharmaceuticals, Inc.
Cardax, Inc
Kowa Company, Ltd.
Segment by Type
ACE Inhibitors
Diuretics
Glucophage
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cardiometabolic Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cardiometabolic Diseases Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ACE Inhibitors
1.2.3 Diuretics
1.2.4 Glucophage
1.2.5 Others
1.3 Market by Application
1.3.1 Global Cardiometabolic Diseases Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cardiometabolic Diseases Market Perspective (2019-2030)
2.2 Cardiometabolic Diseases Growth Trends by Region
2.2.1 Global Cardiometabolic Diseases Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cardiometabolic Diseases Historic Market Size by Region (2019-2024)
2.2.3 Cardiometabolic Diseases Forecasted Market Size by Region (2025-2030)
2.3 Cardiometabolic Diseases Market Dynamics
2.3.1 Cardiometabolic Diseases Industry Trends
2.3.2 Cardiometabolic Diseases Market Drivers
2.3.3 Cardiometabolic Diseases Market Challenges
2.3.4 Cardiometabolic Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cardiometabolic Diseases Players by Revenue
3.1.1 Global Top Cardiometabolic Diseases Players by Revenue (2019-2024)
3.1.2 Global Cardiometabolic Diseases Revenue Market Share by Players (2019-2024)
3.2 Global Cardiometabolic Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cardiometabolic Diseases Revenue
3.4 Global Cardiometabolic Diseases Market Concentration Ratio
3.4.1 Global Cardiometabolic Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cardiometabolic Diseases Revenue in 2023
3.5 Cardiometabolic Diseases Key Players Head office and Area Served
3.6 Key Players Cardiometabolic Diseases Product Solution and Service
3.7 Date of Enter into Cardiometabolic Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cardiometabolic Diseases Breakdown Data by Type
4.1 Global Cardiometabolic Diseases Historic Market Size by Type (2019-2024)
4.2 Global Cardiometabolic Diseases Forecasted Market Size by Type (2025-2030)
5 Cardiometabolic Diseases Breakdown Data by Application
5.1 Global Cardiometabolic Diseases Historic Market Size by Application (2019-2024)
5.2 Global Cardiometabolic Diseases Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cardiometabolic Diseases Market Size (2019-2030)
6.2 North America Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cardiometabolic Diseases Market Size by Country (2019-2024)
6.4 North America Cardiometabolic Diseases Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cardiometabolic Diseases Market Size (2019-2030)
7.2 Europe Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cardiometabolic Diseases Market Size by Country (2019-2024)
7.4 Europe Cardiometabolic Diseases Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cardiometabolic Diseases Market Size (2019-2030)
8.2 Asia-Pacific Cardiometabolic Diseases Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cardiometabolic Diseases Market Size by Region (2019-2024)
8.4 Asia-Pacific Cardiometabolic Diseases Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cardiometabolic Diseases Market Size (2019-2030)
9.2 Latin America Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cardiometabolic Diseases Market Size by Country (2019-2024)
9.4 Latin America Cardiometabolic Diseases Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cardiometabolic Diseases Market Size (2019-2030)
10.2 Middle East & Africa Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cardiometabolic Diseases Market Size by Country (2019-2024)
10.4 Middle East & Africa Cardiometabolic Diseases Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly and Company
11.1.1 Eli Lilly and Company Company Detail
11.1.2 Eli Lilly and Company Business Overview
11.1.3 Eli Lilly and Company Cardiometabolic Diseases Introduction
11.1.4 Eli Lilly and Company Revenue in Cardiometabolic Diseases Business (2019-2024)
11.1.5 Eli Lilly and Company Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Detail
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Cardiometabolic Diseases Introduction
11.2.4 Bayer AG Revenue in Cardiometabolic Diseases Business (2019-2024)
11.2.5 Bayer AG Recent Development
11.3 Arrowhead Pharmaceuticals, Inc
11.3.1 Arrowhead Pharmaceuticals, Inc Company Detail
11.3.2 Arrowhead Pharmaceuticals, Inc Business Overview
11.3.3 Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Introduction
11.3.4 Arrowhead Pharmaceuticals, Inc Revenue in Cardiometabolic Diseases Business (2019-2024)
11.3.5 Arrowhead Pharmaceuticals, Inc Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Cardiometabolic Diseases Introduction
11.4.4 Novartis AG Revenue in Cardiometabolic Diseases Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Company Detail
11.5.2 Boehringer Ingelheim International GmbH Business Overview
11.5.3 Boehringer Ingelheim International GmbH Cardiometabolic Diseases Introduction
11.5.4 Boehringer Ingelheim International GmbH Revenue in Cardiometabolic Diseases Business (2019-2024)
11.5.5 Boehringer Ingelheim International GmbH Recent Development
11.6 Novo Nordisk A/S
11.6.1 Novo Nordisk A/S Company Detail
11.6.2 Novo Nordisk A/S Business Overview
11.6.3 Novo Nordisk A/S Cardiometabolic Diseases Introduction
11.6.4 Novo Nordisk A/S Revenue in Cardiometabolic Diseases Business (2019-2024)
11.6.5 Novo Nordisk A/S Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Cardiometabolic Diseases Introduction
11.7.4 AstraZeneca Revenue in Cardiometabolic Diseases Business (2019-2024)
11.7.5 AstraZeneca Recent Development
11.8 Alnylam Pharmaceuticals, Inc.
11.8.1 Alnylam Pharmaceuticals, Inc. Company Detail
11.8.2 Alnylam Pharmaceuticals, Inc. Business Overview
11.8.3 Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Introduction
11.8.4 Alnylam Pharmaceuticals, Inc. Revenue in Cardiometabolic Diseases Business (2019-2024)
11.8.5 Alnylam Pharmaceuticals, Inc. Recent Development
11.9 Cardax, Inc
11.9.1 Cardax, Inc Company Detail
11.9.2 Cardax, Inc Business Overview
11.9.3 Cardax, Inc Cardiometabolic Diseases Introduction
11.9.4 Cardax, Inc Revenue in Cardiometabolic Diseases Business (2019-2024)
11.9.5 Cardax, Inc Recent Development
11.10 Kowa Company, Ltd.
11.10.1 Kowa Company, Ltd. Company Detail
11.10.2 Kowa Company, Ltd. Business Overview
11.10.3 Kowa Company, Ltd. Cardiometabolic Diseases Introduction
11.10.4 Kowa Company, Ltd. Revenue in Cardiometabolic Diseases Business (2019-2024)
11.10.5 Kowa Company, Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cardiometabolic Diseases Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ACE Inhibitors
1.2.3 Diuretics
1.2.4 Glucophage
1.2.5 Others
1.3 Market by Application
1.3.1 Global Cardiometabolic Diseases Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cardiometabolic Diseases Market Perspective (2019-2030)
2.2 Cardiometabolic Diseases Growth Trends by Region
2.2.1 Global Cardiometabolic Diseases Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cardiometabolic Diseases Historic Market Size by Region (2019-2024)
2.2.3 Cardiometabolic Diseases Forecasted Market Size by Region (2025-2030)
2.3 Cardiometabolic Diseases Market Dynamics
2.3.1 Cardiometabolic Diseases Industry Trends
2.3.2 Cardiometabolic Diseases Market Drivers
2.3.3 Cardiometabolic Diseases Market Challenges
2.3.4 Cardiometabolic Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cardiometabolic Diseases Players by Revenue
3.1.1 Global Top Cardiometabolic Diseases Players by Revenue (2019-2024)
3.1.2 Global Cardiometabolic Diseases Revenue Market Share by Players (2019-2024)
3.2 Global Cardiometabolic Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cardiometabolic Diseases Revenue
3.4 Global Cardiometabolic Diseases Market Concentration Ratio
3.4.1 Global Cardiometabolic Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cardiometabolic Diseases Revenue in 2023
3.5 Cardiometabolic Diseases Key Players Head office and Area Served
3.6 Key Players Cardiometabolic Diseases Product Solution and Service
3.7 Date of Enter into Cardiometabolic Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cardiometabolic Diseases Breakdown Data by Type
4.1 Global Cardiometabolic Diseases Historic Market Size by Type (2019-2024)
4.2 Global Cardiometabolic Diseases Forecasted Market Size by Type (2025-2030)
5 Cardiometabolic Diseases Breakdown Data by Application
5.1 Global Cardiometabolic Diseases Historic Market Size by Application (2019-2024)
5.2 Global Cardiometabolic Diseases Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cardiometabolic Diseases Market Size (2019-2030)
6.2 North America Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cardiometabolic Diseases Market Size by Country (2019-2024)
6.4 North America Cardiometabolic Diseases Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cardiometabolic Diseases Market Size (2019-2030)
7.2 Europe Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cardiometabolic Diseases Market Size by Country (2019-2024)
7.4 Europe Cardiometabolic Diseases Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cardiometabolic Diseases Market Size (2019-2030)
8.2 Asia-Pacific Cardiometabolic Diseases Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cardiometabolic Diseases Market Size by Region (2019-2024)
8.4 Asia-Pacific Cardiometabolic Diseases Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cardiometabolic Diseases Market Size (2019-2030)
9.2 Latin America Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cardiometabolic Diseases Market Size by Country (2019-2024)
9.4 Latin America Cardiometabolic Diseases Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cardiometabolic Diseases Market Size (2019-2030)
10.2 Middle East & Africa Cardiometabolic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cardiometabolic Diseases Market Size by Country (2019-2024)
10.4 Middle East & Africa Cardiometabolic Diseases Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly and Company
11.1.1 Eli Lilly and Company Company Detail
11.1.2 Eli Lilly and Company Business Overview
11.1.3 Eli Lilly and Company Cardiometabolic Diseases Introduction
11.1.4 Eli Lilly and Company Revenue in Cardiometabolic Diseases Business (2019-2024)
11.1.5 Eli Lilly and Company Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Detail
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Cardiometabolic Diseases Introduction
11.2.4 Bayer AG Revenue in Cardiometabolic Diseases Business (2019-2024)
11.2.5 Bayer AG Recent Development
11.3 Arrowhead Pharmaceuticals, Inc
11.3.1 Arrowhead Pharmaceuticals, Inc Company Detail
11.3.2 Arrowhead Pharmaceuticals, Inc Business Overview
11.3.3 Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Introduction
11.3.4 Arrowhead Pharmaceuticals, Inc Revenue in Cardiometabolic Diseases Business (2019-2024)
11.3.5 Arrowhead Pharmaceuticals, Inc Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Cardiometabolic Diseases Introduction
11.4.4 Novartis AG Revenue in Cardiometabolic Diseases Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Company Detail
11.5.2 Boehringer Ingelheim International GmbH Business Overview
11.5.3 Boehringer Ingelheim International GmbH Cardiometabolic Diseases Introduction
11.5.4 Boehringer Ingelheim International GmbH Revenue in Cardiometabolic Diseases Business (2019-2024)
11.5.5 Boehringer Ingelheim International GmbH Recent Development
11.6 Novo Nordisk A/S
11.6.1 Novo Nordisk A/S Company Detail
11.6.2 Novo Nordisk A/S Business Overview
11.6.3 Novo Nordisk A/S Cardiometabolic Diseases Introduction
11.6.4 Novo Nordisk A/S Revenue in Cardiometabolic Diseases Business (2019-2024)
11.6.5 Novo Nordisk A/S Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Cardiometabolic Diseases Introduction
11.7.4 AstraZeneca Revenue in Cardiometabolic Diseases Business (2019-2024)
11.7.5 AstraZeneca Recent Development
11.8 Alnylam Pharmaceuticals, Inc.
11.8.1 Alnylam Pharmaceuticals, Inc. Company Detail
11.8.2 Alnylam Pharmaceuticals, Inc. Business Overview
11.8.3 Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Introduction
11.8.4 Alnylam Pharmaceuticals, Inc. Revenue in Cardiometabolic Diseases Business (2019-2024)
11.8.5 Alnylam Pharmaceuticals, Inc. Recent Development
11.9 Cardax, Inc
11.9.1 Cardax, Inc Company Detail
11.9.2 Cardax, Inc Business Overview
11.9.3 Cardax, Inc Cardiometabolic Diseases Introduction
11.9.4 Cardax, Inc Revenue in Cardiometabolic Diseases Business (2019-2024)
11.9.5 Cardax, Inc Recent Development
11.10 Kowa Company, Ltd.
11.10.1 Kowa Company, Ltd. Company Detail
11.10.2 Kowa Company, Ltd. Business Overview
11.10.3 Kowa Company, Ltd. Cardiometabolic Diseases Introduction
11.10.4 Kowa Company, Ltd. Revenue in Cardiometabolic Diseases Business (2019-2024)
11.10.5 Kowa Company, Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Cardiometabolic Diseases Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of ACE Inhibitors
Table 3. Key Players of Diuretics
Table 4. Key Players of Glucophage
Table 5. Key Players of Others
Table 6. Global Cardiometabolic Diseases Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Cardiometabolic Diseases Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Cardiometabolic Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Cardiometabolic Diseases Market Share by Region (2019-2024)
Table 10. Global Cardiometabolic Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Cardiometabolic Diseases Market Share by Region (2025-2030)
Table 12. Cardiometabolic Diseases Market Trends
Table 13. Cardiometabolic Diseases Market Drivers
Table 14. Cardiometabolic Diseases Market Challenges
Table 15. Cardiometabolic Diseases Market Restraints
Table 16. Global Cardiometabolic Diseases Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Cardiometabolic Diseases Market Share by Players (2019-2024)
Table 18. Global Top Cardiometabolic Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiometabolic Diseases as of 2023)
Table 19. Ranking of Global Top Cardiometabolic Diseases Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Cardiometabolic Diseases Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Cardiometabolic Diseases Product Solution and Service
Table 23. Date of Enter into Cardiometabolic Diseases Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cardiometabolic Diseases Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Cardiometabolic Diseases Revenue Market Share by Type (2019-2024)
Table 27. Global Cardiometabolic Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Cardiometabolic Diseases Revenue Market Share by Type (2025-2030)
Table 29. Global Cardiometabolic Diseases Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Cardiometabolic Diseases Revenue Market Share by Application (2019-2024)
Table 31. Global Cardiometabolic Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Cardiometabolic Diseases Revenue Market Share by Application (2025-2030)
Table 33. North America Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Cardiometabolic Diseases Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Cardiometabolic Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Cardiometabolic Diseases Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 48. Eli Lilly and Company Company Detail
Table 49. Eli Lilly and Company Business Overview
Table 50. Eli Lilly and Company Cardiometabolic Diseases Product
Table 51. Eli Lilly and Company Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 52. Eli Lilly and Company Recent Development
Table 53. Bayer AG Company Detail
Table 54. Bayer AG Business Overview
Table 55. Bayer AG Cardiometabolic Diseases Product
Table 56. Bayer AG Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 57. Bayer AG Recent Development
Table 58. Arrowhead Pharmaceuticals, Inc Company Detail
Table 59. Arrowhead Pharmaceuticals, Inc Business Overview
Table 60. Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Product
Table 61. Arrowhead Pharmaceuticals, Inc Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 62. Arrowhead Pharmaceuticals, Inc Recent Development
Table 63. Novartis AG Company Detail
Table 64. Novartis AG Business Overview
Table 65. Novartis AG Cardiometabolic Diseases Product
Table 66. Novartis AG Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 67. Novartis AG Recent Development
Table 68. Boehringer Ingelheim International GmbH Company Detail
Table 69. Boehringer Ingelheim International GmbH Business Overview
Table 70. Boehringer Ingelheim International GmbH Cardiometabolic Diseases Product
Table 71. Boehringer Ingelheim International GmbH Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 72. Boehringer Ingelheim International GmbH Recent Development
Table 73. Novo Nordisk A/S Company Detail
Table 74. Novo Nordisk A/S Business Overview
Table 75. Novo Nordisk A/S Cardiometabolic Diseases Product
Table 76. Novo Nordisk A/S Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 77. Novo Nordisk A/S Recent Development
Table 78. AstraZeneca Company Detail
Table 79. AstraZeneca Business Overview
Table 80. AstraZeneca Cardiometabolic Diseases Product
Table 81. AstraZeneca Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 82. AstraZeneca Recent Development
Table 83. Alnylam Pharmaceuticals, Inc. Company Detail
Table 84. Alnylam Pharmaceuticals, Inc. Business Overview
Table 85. Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Product
Table 86. Alnylam Pharmaceuticals, Inc. Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 87. Alnylam Pharmaceuticals, Inc. Recent Development
Table 88. Cardax, Inc Company Detail
Table 89. Cardax, Inc Business Overview
Table 90. Cardax, Inc Cardiometabolic Diseases Product
Table 91. Cardax, Inc Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 92. Cardax, Inc Recent Development
Table 93. Kowa Company, Ltd. Company Detail
Table 94. Kowa Company, Ltd. Business Overview
Table 95. Kowa Company, Ltd. Cardiometabolic Diseases Product
Table 96. Kowa Company, Ltd. Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 97. Kowa Company, Ltd. Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cardiometabolic Diseases Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Cardiometabolic Diseases Market Share by Type: 2023 VS 2030
Figure 3. ACE Inhibitors Features
Figure 4. Diuretics Features
Figure 5. Glucophage Features
Figure 6. Others Features
Figure 7. Global Cardiometabolic Diseases Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Cardiometabolic Diseases Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Cardiometabolic Diseases Report Years Considered
Figure 13. Global Cardiometabolic Diseases Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Cardiometabolic Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Cardiometabolic Diseases Market Share by Region: 2023 VS 2030
Figure 16. Global Cardiometabolic Diseases Market Share by Players in 2023
Figure 17. Global Top Cardiometabolic Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiometabolic Diseases as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Cardiometabolic Diseases Revenue in 2023
Figure 19. North America Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 21. United States Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 25. Germany Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Cardiometabolic Diseases Market Share by Region (2019-2030)
Figure 33. China Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 41. Mexico Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 45. Turkey Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Eli Lilly and Company Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 48. Bayer AG Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 49. Arrowhead Pharmaceuticals, Inc Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 50. Novartis AG Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 51. Boehringer Ingelheim International GmbH Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 52. Novo Nordisk A/S Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 53. AstraZeneca Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 54. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 55. Cardax, Inc Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 56. Kowa Company, Ltd. Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Table 1. Global Cardiometabolic Diseases Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of ACE Inhibitors
Table 3. Key Players of Diuretics
Table 4. Key Players of Glucophage
Table 5. Key Players of Others
Table 6. Global Cardiometabolic Diseases Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Cardiometabolic Diseases Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Cardiometabolic Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Cardiometabolic Diseases Market Share by Region (2019-2024)
Table 10. Global Cardiometabolic Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Cardiometabolic Diseases Market Share by Region (2025-2030)
Table 12. Cardiometabolic Diseases Market Trends
Table 13. Cardiometabolic Diseases Market Drivers
Table 14. Cardiometabolic Diseases Market Challenges
Table 15. Cardiometabolic Diseases Market Restraints
Table 16. Global Cardiometabolic Diseases Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Cardiometabolic Diseases Market Share by Players (2019-2024)
Table 18. Global Top Cardiometabolic Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiometabolic Diseases as of 2023)
Table 19. Ranking of Global Top Cardiometabolic Diseases Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Cardiometabolic Diseases Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Cardiometabolic Diseases Product Solution and Service
Table 23. Date of Enter into Cardiometabolic Diseases Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cardiometabolic Diseases Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Cardiometabolic Diseases Revenue Market Share by Type (2019-2024)
Table 27. Global Cardiometabolic Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Cardiometabolic Diseases Revenue Market Share by Type (2025-2030)
Table 29. Global Cardiometabolic Diseases Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Cardiometabolic Diseases Revenue Market Share by Application (2019-2024)
Table 31. Global Cardiometabolic Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Cardiometabolic Diseases Revenue Market Share by Application (2025-2030)
Table 33. North America Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Cardiometabolic Diseases Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Cardiometabolic Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Cardiometabolic Diseases Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Cardiometabolic Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Cardiometabolic Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Cardiometabolic Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 48. Eli Lilly and Company Company Detail
Table 49. Eli Lilly and Company Business Overview
Table 50. Eli Lilly and Company Cardiometabolic Diseases Product
Table 51. Eli Lilly and Company Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 52. Eli Lilly and Company Recent Development
Table 53. Bayer AG Company Detail
Table 54. Bayer AG Business Overview
Table 55. Bayer AG Cardiometabolic Diseases Product
Table 56. Bayer AG Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 57. Bayer AG Recent Development
Table 58. Arrowhead Pharmaceuticals, Inc Company Detail
Table 59. Arrowhead Pharmaceuticals, Inc Business Overview
Table 60. Arrowhead Pharmaceuticals, Inc Cardiometabolic Diseases Product
Table 61. Arrowhead Pharmaceuticals, Inc Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 62. Arrowhead Pharmaceuticals, Inc Recent Development
Table 63. Novartis AG Company Detail
Table 64. Novartis AG Business Overview
Table 65. Novartis AG Cardiometabolic Diseases Product
Table 66. Novartis AG Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 67. Novartis AG Recent Development
Table 68. Boehringer Ingelheim International GmbH Company Detail
Table 69. Boehringer Ingelheim International GmbH Business Overview
Table 70. Boehringer Ingelheim International GmbH Cardiometabolic Diseases Product
Table 71. Boehringer Ingelheim International GmbH Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 72. Boehringer Ingelheim International GmbH Recent Development
Table 73. Novo Nordisk A/S Company Detail
Table 74. Novo Nordisk A/S Business Overview
Table 75. Novo Nordisk A/S Cardiometabolic Diseases Product
Table 76. Novo Nordisk A/S Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 77. Novo Nordisk A/S Recent Development
Table 78. AstraZeneca Company Detail
Table 79. AstraZeneca Business Overview
Table 80. AstraZeneca Cardiometabolic Diseases Product
Table 81. AstraZeneca Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 82. AstraZeneca Recent Development
Table 83. Alnylam Pharmaceuticals, Inc. Company Detail
Table 84. Alnylam Pharmaceuticals, Inc. Business Overview
Table 85. Alnylam Pharmaceuticals, Inc. Cardiometabolic Diseases Product
Table 86. Alnylam Pharmaceuticals, Inc. Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 87. Alnylam Pharmaceuticals, Inc. Recent Development
Table 88. Cardax, Inc Company Detail
Table 89. Cardax, Inc Business Overview
Table 90. Cardax, Inc Cardiometabolic Diseases Product
Table 91. Cardax, Inc Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 92. Cardax, Inc Recent Development
Table 93. Kowa Company, Ltd. Company Detail
Table 94. Kowa Company, Ltd. Business Overview
Table 95. Kowa Company, Ltd. Cardiometabolic Diseases Product
Table 96. Kowa Company, Ltd. Revenue in Cardiometabolic Diseases Business (2019-2024) & (US$ Million)
Table 97. Kowa Company, Ltd. Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cardiometabolic Diseases Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Cardiometabolic Diseases Market Share by Type: 2023 VS 2030
Figure 3. ACE Inhibitors Features
Figure 4. Diuretics Features
Figure 5. Glucophage Features
Figure 6. Others Features
Figure 7. Global Cardiometabolic Diseases Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Cardiometabolic Diseases Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Cardiometabolic Diseases Report Years Considered
Figure 13. Global Cardiometabolic Diseases Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Cardiometabolic Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Cardiometabolic Diseases Market Share by Region: 2023 VS 2030
Figure 16. Global Cardiometabolic Diseases Market Share by Players in 2023
Figure 17. Global Top Cardiometabolic Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiometabolic Diseases as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Cardiometabolic Diseases Revenue in 2023
Figure 19. North America Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 21. United States Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 25. Germany Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Cardiometabolic Diseases Market Share by Region (2019-2030)
Figure 33. China Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 41. Mexico Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Cardiometabolic Diseases Market Share by Country (2019-2030)
Figure 45. Turkey Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Cardiometabolic Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Eli Lilly and Company Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 48. Bayer AG Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 49. Arrowhead Pharmaceuticals, Inc Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 50. Novartis AG Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 51. Boehringer Ingelheim International GmbH Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 52. Novo Nordisk A/S Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 53. AstraZeneca Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 54. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 55. Cardax, Inc Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 56. Kowa Company, Ltd. Revenue Growth Rate in Cardiometabolic Diseases Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232